Diagnosing Non-Ischemic Cardiomyopathies on Myocardial Perfusion Imaging with Positron Emission Tomography

Roopesh Sai Jakulla,Brett W. Sperry

DOI: https://doi.org/10.1007/s11886-024-02139-x

IF: 3.955

2024-09-23

Current Cardiology Reports

Abstract:This article summarizes findings seen in various cardiomyopathies on myocardial perfusion imaging (MPI) with positron emission tomography (PET).

cardiac & cardiovascular systems

What problem does this paper attempt to address?

Myocardial perfusion imaging with PET

Roel S. Driessen,Pieter G. Raijmakers,Wijnand J. Stuijfzand,Paul Knaapen

DOI: https://doi.org/10.1007/s10554-017-1084-4

2017-02-10

The International Journal of Cardiovascular Imaging

Abstract:Noninvasive assessment of coronary artery disease remains a challenging task, with a large armamentarium of diagnostic modalities. Myocardial perfusion imaging (MPI) is widely used for this purpose whereby cardiac positron emission tomography (PET) is considered the gold standard. Next to relative radiotracer distribution, PET allows for measurement of absolute myocardial blood flow. This quantification of perfusion improves diagnostic accuracy and prognostic value. Cardiac hybrid imaging relies on the fusion of anatomical and functional imaging using coronary computed tomography angiography and MPI, respectively, and provides incremental value as compared with either stand-alone modality.
Role of Positron Emission Tomography Cardiac Perfusion Imaging in Clinical Management, Prognosis, and Risk Stratification of Cardiovascular Disease

Vijay Singh,Lokeshwaran M. Kalimuthu,Ayush Mishra,Manish Ora,Sanjay Gambhir,Aftab Hasan Nazar

DOI: https://doi.org/10.1177/26324636231174797

2023-05-18

Indian Journal of Clinical Cardiology

Abstract:Coronary artery disease (CAD) is an important cause of morbidity and mortality worldwide. Perfusion abnormalities precede wall motion abnormalities, ECG changes, and angina in the etiology of CAD. myocardial perfusion imaging (MPI) can detect perfusion alterations due to pathology at sites such as the endothelium, microvasculature, and epicardial coronary arteries. Thus, it measures the universal burden of ischemic heart disease (IHD). Nuclear medicine MPI is an important noninvasive imaging modality to evaluate the perfusion of the myocardium. Positron Emission Tomography (PET) and single-photon emission computed tomography (SPECT) with or without computed tomography (CT) are 2 primary modalities. PET is a highly sensitive modality with an inherent ability to quantify absolute myocardial blood flow (MBF) and variations in MBF due to various stress agents. PET has immense potential to change clinical management, prognosticate, and risk stratify patients presenting with clinical or preclinical CAD. Evidence shows that early PET detection of myocardial perfusion abnormalities, followed by aggressive intervention for cardiovascular risk factors, can reinstate myocardial perfusion. This may reduce morbidity and mortality. We shall be reviewing the clinical impact of PET in CAD and preclinical CAD patients.
Clinical Application of PET Myocardial Perfusion Imaging

Zhi Jiang,Jianan Wang,Hong Zhang

DOI: https://doi.org/10.2174/157340512803759802

2012-01-01

Current Medical Imaging Formerly Current Medical Imaging Reviews

Abstract:Coronary artery disease is the major cause of death in developed countries. PET myocardial perfusion image has become more important in the diagnosis and risk stratification for coronary artery disease patients. The available evidence supported that PET is the "gold standard" for detecting myocardial perfusion, comparing to other noninvasive assessment techniques. Its ability to quantify absolute myocardial blood flow and evaluate left ventricle function from rest to stress provides an extra value in multi-vessel disease and prognosis. As the development of scanners, software, novel radiotracers, hybrid imaging technique and the emerging clinical evidence, the clinical application of PET will be further enhanced in the near future. This review summarized clinical application of PET myocardial perfusion imaging and its new developments.
Diagnosis of Coronary Artery Disease with 99Tcm-N-noet Myocardial Perfusion Imaging

Zhong-jie Fan,Li-bo Chen,Yan-rong Du,Qing-ming Long,Quan Fang,Shu-yang Zhang,Xiao-wei Yan,Zhu-jun Shen,Xiao-feng Jin,Jian-zhong Shen,De-li Zhang,Wen-ling Zhu,Fang Li

DOI: https://doi.org/10.3760/j:issn:0376-2491.2006.26.011

2006-01-01

Abstract:OBJECTIVE:To evaluate the sensitivity and specificity of (99)Tc(m)-N-NOET myocardial perfusion tomographic imaging (MPI) for the diagnosis of coronary artery disease (CAD).METHODS:Coronary angiography and (99)Tc(m)-N-NOET myocardial perfusion tomographic imaging were performed in the patients hospitalized in the Department of Cardiology, Peking Union Medical College Hospital, from June to December 2005 with known or suspected diagnosis of CAD. Adenosine was infused intravenously at a rate of 140 microg x kg(-1)min(-1) for 6 minutes. At the third minute of adenosine infusion, 740 MBq (20 mCi) (99)Tc(m)-N-NOET was injected intravenously. MPI was obtained 15 minutes after the (99)Tc(m)-N-NOET infusion. If the result was abnormal, rest myocardial perfusion imaging would be performed 2 hours later. Coronary angiography was performed in all patients within one week after the myocardial perfusion imaging.RESULTS:Myocardial perfusion imaging was performed in 53 cases, 36 males and 17 females, aged 56 +/- 10, who underwent coronary angiography, among which 31 had > or = 50% stenosis of coronary artery and 23 had normal coronary artery. All of the patients with stenosis of coronary artery had positive (99)Tc(m)-N-NOET adenosine stress myocardial perfusion imaging. Nineteen out of the 29 cases without stenosis of coronary artery had negative adenosine myocardial perfusion imaging. The sensitivity and specificity of (99)Tc(m)-N-NOET adenosine myocardial perfusion imaging were 100% and 73% respectively in the detection of stenosis of coronary arteries. Seven cases got percutaneous coronary intervention and 2 got coronary artery bypass graft. Six of the 9 patients undergoing revascularization had stenosis of stents or grafts, 5 of which had positive myocardial perfusion imaging. 3 cases hadn't restenosis and their results of myocardial perfusion imaging were negative.CONCLUSION:(99)Tc(m)-N-NOET myocardial perfusion imaging is a useful non-interventional method for detecting coronary artery stenosis.
Comparative effectiveness of positron emission tomography and single-photon emission computed tomography myocardial perfusion imaging for predicting risk in patients with cardiometabolic disease

Daniel M Huck,Sanjay Divakaran,Brittany Weber,Jenifer M Brown,Diana Lopez,Ana Carolina do A H Souza,Jon Hainer,Ron Blankstein,Sharmila Dorbala,Marcelo Di Carli

DOI: https://doi.org/10.1016/j.nuclcard.2024.101908

Abstract:Background: The epidemiology of coronary artery disease (CAD) has shifted, with increasing prevalence of cardiometabolic disease and decreasing findings of obstructive CAD on myocardial perfusion imaging (MPI). Coronary microvascular dysfunction (CMD), defined as impaired myocardial flow reserve (MFR) by positron emission tomography (PET), has emerged as a key mediator of risk. We aimed to assess whether PET MFR provides additive value for risk stratification of cardiometabolic disease patients compared with single-photon emission computed tomography (SPECT) MPI. Methods: We retrospectively followed patients referred for PET, exercise SPECT, or pharmacologic SPECT MPI with cardiometabolic disease (obesity, diabetes, or chronic kidney disease) and without known CAD. We compared rates and hazards of composite major adverse cardiovascular events (MACEs) (annualized cardiac mortality or acute myocardial infarction) among propensity-matched PET and SPECT patients using Poisson and Cox regression. Normal SPECT was defined as a total perfusion deficit (TPD) of <5%, reflecting the absence of obstructive CAD. Normal PET was defined as a TPD of <5% plus an MFR of ≥2.0. Results: Among 21,544 patients referred from 2006 to 2020, cardiometabolic disease was highly prevalent (PET: 2308 [67%], SPECT: 9984 [55%]) and higher among patients referred to PET (P < 0.001). Obstructive CAD findings (TPD > 5%) were uncommon (PET: 21% and SPECT: 11%). Conversely, impaired MFR on PET (<2.0) was common (62%). In a propensity-matched analysis over a median 6.4-year follow-up, normal PET identified low-risk (0.9%/year MACE) patients, and abnormal PET identified high-risk (4.2%/year MACE) patients with cardiometabolic disease; conversely, those with normal pharmacologic SPECT remained moderate-risk (1.6%/year, P < 0.001 compared to normal PET). Conclusions: Cardiometabolic disease is common among patients referred for MPI and is associated with a heterogenous level of risk. Compared with pharmacologic SPECT, PET with MFR can detect nonobstructive CAD including CMD and can more accurately discriminate low-risk from higher-risk individuals.
Myocardial ischemia in patients with large prior infarction: Clinical decision making and review of literature

Talal Asif,Rami Doukky

DOI: https://doi.org/10.1016/j.radcr.2022.11.006

2022-11-25

Abstract:Myocardial perfusion imaging (MPI) with single photon emission computed tomography (SPECT) or positron emission tomography (PET) is a widely used technique for the evaluation of coronary artery disease (CAD). Interpreting physicians rely on regional variations in myocardial radiotracer uptake between rest and stress images to identify hemodynamically significant epicardial coronary artery stenosis. However, interpretation of MPI is very difficult in patients with large infarcts where there is no scintigraphically normal reference myocardium for comparison. In these patients, the stress and rest images appear similar due to balanced ischemia in the non-infarct territory. There are no clear guidelines on how to approach these cases. We present a case of MPI with a large right coronary artery territory (RCA) infarct where the left main (LM) coronary artery territory has no relative comparator and the images looked the same on stress and rest. However, the patient had multiple high-risk ancillary findings including electrocardiographic (ECG) changes with regadenoson, transient ischemic dilatation (TID), large severe inferior infarct, low myocardial blood flow (MBF) and myocardial flow reserve (MFR), but most notably increased right ventricular (RV) uptake on the stress images that was a subtle clue that we were dealing with LM equivalent in non-infarct zone. The coronary angiogram confirmed our findings. Through our case, we provide a comprehensive approach and review of literature on how to approach such challenging encounters.
PET imaging in heart failure: the role of new tracers

Antti Saraste,Juhani Knuuti

DOI: https://doi.org/10.1007/s10741-017-9620-9

Abstract:Positron emission tomography (PET) myocardial perfusion imaging is being increasingly used for the detection of coronary artery disease. In the presence of significant left ventricle dysfunction, the assessment of myocardial ischemia and viability by PET plays a role in the identification of patients who may benefit from revascularization. In addition to these, new PET tracers may play a role in the assessment of underlying pathophysiology and therapeutic options in heart failure. Studies have shown the ability of sympathetic innervation imaging to assess the risk of cardiac death, arrhythmia, and disease progression. New tracers have been tested for the assessment of angiogenesis and other mechanisms involved in myocardial repair after infarction. Furthermore, new tracers may play a role in detection of inflammatory cardiomyopathies, especially cardiac sarcoidosis, which is a diagnostic challenge for current methods. In addition to the assessment of prognosis and etiology, the value of new PET tracers will depend on their ability to guide selection of therapies and incorporation into clinical management algorithms in heart failure. This review describes recent advances in applications of cardiac PET in heart failure with emphasis on potential roles of new tracers.
PET/CT Myocardial Perfusion Imaging Acquisition and Processing: Ten Tips and Tricks to Help You Succeed

Talal Alnabelsi,Akanksha Thakkar,Ahmed Ibrahim Ahmed,Yushui Han,Mouaz H. Al-Mallah

DOI: https://doi.org/10.1007/s11886-021-01476-5

IF: 3.955

2021-03-11

Current Cardiology Reports

Abstract:Positron emission tomography (PET) is a leading non-invasive modality for the diagnosis of coronary artery disease due to its diagnostic accuracy and high image quality. With the latest advances in PET systems, clinicians are able to assess for myocardial ischemia and myocardial blood flow while exposing patients to extremely low radiation doses. This review will focus on the basics of acquisition and processing of hybrid PET/CT systems from appropriate patient selection to common artifacts and pitfalls.

cardiac & cardiovascular systems
Myocardial perfusion imaging combined with computed tomography coronary angiography in the diagnosis and treat-ment of coronary heart disease

Shu LIU,Yanyang LIU,Xuemei WANG,Guojian ZHANG

DOI: https://doi.org/10.3969/j.issn.1671-6450.2014.08.003

2014-01-01

Abstract:Objective To investigate myocardial perfusion imaging (MPI) combined with coronary CT angiography (CTA) in diagnosis of "culprit"coronary artery.Methods From 2012 February-2013 December, hospitalized patients with coronary heart disease (33 cases) were enrolled, male of 25 cases, female of 8 cases, age from 35 to 75 years old (55.2 ± 20.2), they were underwent13 N-NH3 PET adenosine /resting MPI and coronary artery CTA examination , within 1 months of coronary arteriography (CAG), respectively.The MPI, CTA and CAG were analyzed;using CAG as golden standard, the di-agnostic value of coronary CTA , MPI and MPI combined coronary artery CTA were analyzed .Results (1) The sensitivity of CTA in diagnosis of coronary heart disease was 90.0%(36/40), the specificity was 95.0%(302/318), the positive predic-tive value was 69.2%(36/52), the negative predictive value was 98.7%(302/306).(2) The sensitivity of MPI in diagno-sis of coronary heart disease was 90.9% (20/22), the specificity was 90.9% (10/11), the positive predictive value was 95.2%(20/21), the negative predictive value was 83.3%(10/12).(3) The sensitivity of MPI combined with CTA in diag-nosis of coronary heart disease was 95.5%(20/21), the specificity was 100% (11/11), the positive predictive value was 100%(21/21), the negative predictive value was 91.7%(11/12).Conclusion MPI combined with coronary CTA can de-crease the"false positive"and"false negative"results caused by MPI or CTA alone , provides higher accuracy for the diagno-sis and treatment of coronary heart disease , especially to improve the detection rate of "culprit"vessel.
PET-determined myocardial perfusion and flow in coronary artery disease characterization

Ines Valenta,Thomas H Schindler

DOI: https://doi.org/10.1016/j.jmir.2024.02.010

Abstract:Positron emission tomography (PET) myocardial perfusion imaging in conjunction with tracer-kinetic modeling enables the concurrent assessment of myocardial perfusion and regional myocardial blood flow (MBF) of the left ventricle in absolute terms in milliliters per gram per minute (mL/g/min). The non-invasive quantification of MBF during pharmacologically induced hyperemia, at rest, and corresponding myocardial flow reserve (MFR) opens a new avenue for the identification and characterization of classical or endogen type of coronary microvascular dysfunction (CMD) as functional substrate for microvascular angina in patients with non-obstructive coronary artery disease (CAD) and/or no CAD at all. Further, PET-MBF quantification expands the scope of conventional myocardial perfusion imaging from the identification of advanced, and flow-limiting, epicardial CAD to early stages of atherosclerosis and/or CMD. Adding MBF assessment to myocardial perfusion may also reliably unravel diffuse ischemia owing to significant left main stenosis and/or multivessel CAD, commonly confirmed by peak stress transient ischemic cavity dilation of the left ventricle during maximal vasomotor stress compared to rest on gated PET images. Owing to high spatial and contrast resolution in conjunction with photon-attenuation free myocardial perfusion PET images, PET is preferentially used for CAD detection in advanced obesity and women with pronounced breast habitus. With increasing clinical use of cardiac PET perfusion and MBF assessment, individualized, and image-guided cardiovascular treatment decisions in CAD patients is likely to ensue, while its translation into improved cardiovascular outcome remains to be investigated.
Advances in Myocardial Perfusion MR Imaging: Physiological Implications, the Importance of Quantitative Analysis, and Impact on Patient Care in Coronary Artery Disease

Hajime Sakuma,Masaki Ishida

DOI: https://doi.org/10.2463/mrms.rev.2021-0033

2022-03-01

Abstract:Stress myocardial perfusion imaging (MPI) is the preferred test in patients with intermediate-to-high clinical likelihood of coronary artery disease (CAD) and can be used as a gatekeeper to avoid unnecessary revascularization. Cardiac magnetic resonance (CMR) has a number of favorable characteristics, including: (1) high spatial resolution that can delineate subendocardial ischemia; (2) comprehensive assessment of morphology, global and regional cardiac functions, tissue characterization, and coronary artery stenosis; and (3) no radiation exposure to patients. According to meta-analysis studies, the diagnostic accuracy of perfusion CMR is comparable to positron emission tomography (PET) and perfusion CT, and is better than single-photon emission CT (SPECT) when fractional flow reserve (FFR) is used as a reference standard. In addition, stress CMR has an excellent prognostic value. One meta-analysis study demonstrated the annual event rate of cardiovascular death or non-fatal myocardial infarction was 4.9% and 0.8%, respectively, in patients with positive and negative stress CMR. Quantitative assessment of perfusion CMR not only allows the objective evaluation of regional ischemia but also provides insights into the pathophysiology of microvascular disease and diffuse subclinical atherosclerosis. For accurate quantification of myocardial perfusion, saturation correction of arterial input function is important. There are two major approaches for saturation correction, one is a dual-bolus method and the other is a dual-sequence method. Absolute quantitative mapping with myocardial perfusion CMR has good accuracy in detecting coronary microvascular dysfunction. Flow measurement in the coronary sinus (CS) with phase contrast cine CMR is an alternative approach to quantify global coronary flow reserve (CFR). The measurement of global CFR by quantitative analysis of perfusion CMR or flow measurement in the CS permits assessment of microvascular disease and diffuse subclinical atherosclerosis, which may provide improved prediction of future event risk in patients with suspected or known CAD. Multi-institutional studies to validate the diagnostic and prognostic values of quantitative perfusion CMR approaches are required.
Positron emission tomography imaging in cardiovascular disease

Jason M Tarkin,Andrej Ćorović,Christopher Wall,Deepa Gopalan,James HF Rudd

DOI: https://doi.org/10.1136/heartjnl-2019-315183

IF: 5.7

2020-06-22

Heart

Abstract:Positron emission tomography (PET) imaging is useful in cardiovascular disease across several areas, from assessment of myocardial perfusion and viability, to highlighting atherosclerotic plaque activity and measuring the extent of cardiac innervation in heart failure. Other important roles of PET have emerged in prosthetic valve endocarditis, implanted device infection, infiltrative cardiomyopathies, aortic stenosis and cardio-oncology. Advances in scanner technology, including hybrid PET/MRI and total body PET imaging, as well as the development of novel PET tracers and cardiac-specific postprocessing techniques using artificial intelligence will undoubtedly continue to progress the field.

cardiac & cardiovascular systems
Exercise 18 FDG Imaging for the Detection of CAD: What Are the Clinical Hurdles?

Diwakar Jain,Zuo-Xiang He,Afshin Ghanbarinia

DOI: https://doi.org/10.1007/s11886-010-0087-8

IF: 3.955

2010-01-01

Current Cardiology Reports

Abstract:Myocardial perfusion imaging (MPI) has been in clinical use for over 30 years, providing an effective, reliable, and relatively simple tool for diagnosis, risk stratification, and follow-up of patients with suspected or know coronary artery disease (CAD). The unique strength of nuclear imaging is its ability to provide tools for imaging biochemical and metabolic processes, and receptor and transporter functions at molecular and cellular levels in intact organisms under various physiologic conditions. Metabolic imaging using radiolabeled glucose analogues ((18)F-fluorodeoxyglucose [(18)FDG]) provides a unique ability to image myocardial ischemia directly ("hot spot" imaging) in patients with known or suspected CAD. Exercise (18)FDG imaging can potentially overcome some of the limitations of currently used stress-rest MPI. In this article, we describe recent studies using exercise (18)FDG for imaging myocardial ischemia and its potential use in routine clinical practice.
The prognostic value of non-perfusion variables obtained during vasodilator stress myocardial perfusion imaging

Navkaranbir S Bajaj,Siddharth Singh,Ayman Farag,Stephanie El-Hajj,Jack Heo,Ami E Iskandrian,Fadi G Hage

DOI: https://doi.org/10.1007/s12350-016-0441-3

Abstract:Myocardial perfusion imaging (MPI) is an established diagnostic test that provides useful prognostic data in patients with known or suspected coronary artery disease. In more than half of the patients referred for stress testing, vasodilator stress is used in lieu of exercise. Unlike exercise, vasodilator stress does not provide information on exercise and functional capacity, heart rate recovery, and chronotropy, and ECG changes are less frequent. These non-perfusion data provide important prognostic and patient management information. Further, event rates in patients undergoing vasodilator MPI are higher than in those undergoing exercise MPI and even in those with normal images probably due to higher pretest risk. However, there are a number of non-perfusion variables that are obtained during vasodilator stress testing, which have prognostic relevance but their use has not been well emphasized. The purpose of this review is to summarize the prognostic values of these non-perfusion data obtained during vasodilator MPI.
Positron Emission Tomography in Heart Failure: From Pathophysiology to Clinical Application

Gregorio Tersalvi,Vittorio Beltrani,Martin R Grübler,Alessandra Molteni,Yvonne Cristoforetti,Giovanni Pedrazzini,Giorgio Treglia,Luigi Biasco

DOI: https://doi.org/10.3390/jcdd10050220

2023-05-17

Abstract:Imaging modalities are increasingly being used to evaluate the underlying pathophysiology of heart failure. Positron emission tomography (PET) is a non-invasive imaging technique that uses radioactive tracers to visualize and measure biological processes in vivo. PET imaging of the heart uses different radiopharmaceuticals to provide information on myocardial metabolism, perfusion, inflammation, fibrosis, and sympathetic nervous system activity, which are all important contributors to the development and progression of heart failure. This narrative review provides an overview of the use of PET imaging in heart failure, highlighting the different PET tracers and modalities, and discussing fields of present and future clinical application.
Radiomics for the detection of diffusely impaired myocardial perfusion: A proof-of-concept study using 13N-ammonia positron emission tomography

Ganna Degtiarova,Chrysoula Garefa,Reto Boehm,Domenico Ciancone,Daniel Sepulcri,Catherine Gebhard,Andreas A. Giannopoulos,Aju P. Pazhenkottil,Philipp A. Kaufmann,Ronny R. Buechel

DOI: https://doi.org/10.1007/s12350-022-03179-y

2023-01-06

Journal of Nuclear Cardiology

Abstract:The current proof-of-concept study investigates the value of radiomic features from normal 13N-ammonia positron emission tomography (PET) myocardial retention images to identify patients with reduced global myocardial flow reserve (MFR).

radiology, nuclear medicine & medical imaging,cardiac & cardiovascular systems
Characterization of myocardial perfusion imaging systems - an extension of quality metrics

Dea Dundara Debeljuh,Roberta Matheoud,Orazio Zoccarato,Ivan Pribanić,Marco Brambilla,Slaven Jurković

DOI: https://doi.org/10.1016/j.ejmp.2024.104510

2024-08-30

Abstract:Purpose: The aim of this study was to evaluate the performance of myocardial perfusion imaging (MPI) systems in detecting perfusion defects (PDs). The defect perfusion index (DPI) was introduced to extend and further advance the current MPI quality metrics. Methods: An anthropomorphic phantom simulating normal and pathological myocardial perfusion conditions was imaged by various NaI-crystal detector systems with and without corrections for scatter (SC) and attenuation (AC) (Symbia, Symbia + SC, Symbia IQ + SCAC, Symbia IQ), and cadmium-zinc-telluride detector systems without corrections (DSPECT, D530c). The extent of PD and the summed score (SS) were obtained by comparing polar maps with ad hoc normal databases created for each MPI system by using phantom polar maps with normal perfusion. The segmental uptake (SU) and the global uniformity (GU) were evaluated. The DPI was calculated on segments included in the PD to minimize attenuation artifacts outside the PD. The 17 segmental model was used. Results: The highest level of uniformity of polar map was obtained for Symbia IQ + SCAC. D530c showed the highest extent of PD and dependence of the extent on the PD position. It showed in general the lowest SU values and the highest GU due to attenuation artifacts. Nevertheless, D530c outperforms other MPI systems in terms of PD detection, showing the highest DPI value. DSPECT system showed the lowest SS value, and DPI values comparable to NaI-crystal detector systems. Conclusion: The DPI can be evaluated to investigate the intrinsic ability of MPI systems to detect PDs, whatever the quantitative post-processing software used.
Impact of CT attenuation correction on viable myocardium detection in combined SPECT and PET/CT: A retrospective cohort study

Fukai Zhao,Yue Chen,Jiaming Zhao,Zekun Pang,Jiao Wang,Bing Cao,Jianming Li

DOI: https://doi.org/10.1097/md.0000000000040175

IF: 1.6

2024-10-30

Medicine

Abstract:The combination of Technetium-99m-methoxyisobutylisonitrile (Tc-99m-MIBI) single-photon emission computed tomography (SPECT) and Fluorine-18-fluorodeoxyglucose (F-18-FDG) Positron Emission Tomography/Computed Tomography (PET/CT) for myocardial perfusion/metabolic imaging is commonly used to assess myocardial viability, guide treatment strategies, and predict outcomes in patients with ischemic heart failure. [ 1 , 2 ] Hibernating myocardium (HM) is a chronic and potentially reversible myocardial dysfunction caused by ischemia. In myocardial viability imaging, perfusion-metabolism mismatch is considered a characteristic feature of HM, whereas a decrease or lack of perfusion/metabolism match indicates the presence of infarct scar tissue. [ 3 , 4 ] Research evidence suggests that the extent of functional improvement in the heart after revascularization is positively correlated with the proportion of hibernating myocardium. [ 5 ] Hence, the presence and proportion of HM and scars are critical for determining the suitability for revascularization, where more HM and fewer scars correlate with a better potential for recovery and prognosis. Therefore, an accurate assessment of HM and scars is crucial for clinical decision-making. Clinical studies [ 6 ] have shown that timely coronary revascularization to restore blood flow to the HM can improve the symptoms and prognosis of patients with ischemic heart failure. While PET/CT myocardial perfusion imaging (MPI) generally provides high-quality imaging with reduced impact from soft tissue attenuation, making it ideal for evaluating myocardial blood flow, it is not entirely free from attenuation effects. Moreover, its widespread clinical application is limited by factors such as the availability of PET/CT facilities, accessibility, and the cost of positron-emitting radiopharmaceuticals. Consequently, most clinical practice studies [ 7–9 ] have employed SPECT MPI. However, SPECT MPI is known to suffer from attenuation artifacts caused by uneven absorption of low-energy gamma photons by the breast, diaphragm, and chest wall muscles, which can lead to false positives or exacerbate perceived reductions in perfusion. [ 10 , 11 ] Our search revealed that some large-scale multicenter clinical studies, such as the STICH trial, [ 12 ] used SPECT MPI without combining it with PET/CT metabolic imaging or applying attenuation correction (AC). Furthermore, recent studies [ 8 , 13–18 ] assessing myocardial viability using SPECT MPI combined with F-18-FDG PET/CT did not analyze AC-corrected SPECT data. In patients with ischemic heart failure, the enlarged heart could further exacerbate the range and severity of attenuation artifacts, potentially leading to greater misestimation of perfusion deficits, which could, in turn, affect the calculation results of HM, Scar, and other normal myocardial areas when combined with PET/CT metabolic imaging, thereby affecting the accuracy of myocardial viability and type calculations.

medicine, general & internal
Myocardial Blood Flow Quantification for Evaluation of Coronary Artery Disease by Positron Emission Tomography, Cardiac Magnetic Resonance Imaging, and Computed Tomography

Alfonso H. Waller,Ron Blankstein,Raymond Y. Kwong,Marcelo F. Di Carli

DOI: https://doi.org/10.1007/s11886-014-0483-6

IF: 3.955

2014-04-10

Current Cardiology Reports

Abstract:The noninvasive detection of the presence and functional significance of coronary artery stenosis is important in the diagnosis, risk assessment, and management of patients with known or suspected coronary artery disease. Quantitative assessment of myocardial perfusion can provide an objective and reproducible estimate of myocardial ischemia and risk prediction. Positron emission tomography, cardiac magnetic resonance, and cardiac computed tomography perfusion are modalities capable of measuring myocardial blood flow and coronary flow reserve. In this review, we will discuss the technical aspects of quantitative myocardial perfusion imaging with positron emission tomography, cardiac magnetic resonance imaging, and computed tomography, and its emerging clinical applications.

cardiac & cardiovascular systems
The role of cardiac PET in diagnosis and prognosis of patients with ischemia with no obstructive coronary arteries (INOCA)

Mouaz H Al-Mallah,Malek Nayfeh,Mahmoud Alrifai

DOI: https://doi.org/10.1016/j.ahjo.2024.100399

2024-05-18

Abstract:Chest pain, a common symptom in cardiovascular care, often leads to the investigation of obstructive coronary artery disease (CAD). However, many patients experience chest pain without obstructive CAD, termed INOCA (Ischemia with Non-Obstructive Coronary Arteries) or CMD (Coronary Microvascular Dysfunction). INOCA can be attributed to endothelial dysfunction, vascular smooth muscle dysfunction, or both, affecting about 20-30 % of patients with nonobstructive CAD. The diagnostic approach for INOCA includes both invasive and non-invasive methods, with cardiac PET (Positron Emission Tomography) playing a significant role in risk stratification and management. PET evaluates various parameters like myocardial blood flow under stress and rest, myocardial flow reserve, and myocardial ischemia. Such comprehensive assessment is essential in accurately diagnosing and managing INOCA, considering the complexity of this condition.

Diagnosing Non-Ischemic Cardiomyopathies on Myocardial Perfusion Imaging with Positron Emission Tomography

Myocardial perfusion imaging with PET

Role of Positron Emission Tomography Cardiac Perfusion Imaging in Clinical Management, Prognosis, and Risk Stratification of Cardiovascular Disease

Clinical Application of PET Myocardial Perfusion Imaging

Diagnosis of Coronary Artery Disease with 99Tcm-N-noet Myocardial Perfusion Imaging

Comparative effectiveness of positron emission tomography and single-photon emission computed tomography myocardial perfusion imaging for predicting risk in patients with cardiometabolic disease

Myocardial ischemia in patients with large prior infarction: Clinical decision making and review of literature

PET imaging in heart failure: the role of new tracers

PET/CT Myocardial Perfusion Imaging Acquisition and Processing: Ten Tips and Tricks to Help You Succeed

Myocardial perfusion imaging combined with computed tomography coronary angiography in the diagnosis and treat-ment of coronary heart disease

PET-determined myocardial perfusion and flow in coronary artery disease characterization

Advances in Myocardial Perfusion MR Imaging: Physiological Implications, the Importance of Quantitative Analysis, and Impact on Patient Care in Coronary Artery Disease

Positron emission tomography imaging in cardiovascular disease

Exercise 18 FDG Imaging for the Detection of CAD: What Are the Clinical Hurdles?

The prognostic value of non-perfusion variables obtained during vasodilator stress myocardial perfusion imaging

Positron Emission Tomography in Heart Failure: From Pathophysiology to Clinical Application

Radiomics for the detection of diffusely impaired myocardial perfusion: A proof-of-concept study using 13N-ammonia positron emission tomography

Characterization of myocardial perfusion imaging systems - an extension of quality metrics

Impact of CT attenuation correction on viable myocardium detection in combined SPECT and PET/CT: A retrospective cohort study

Myocardial Blood Flow Quantification for Evaluation of Coronary Artery Disease by Positron Emission Tomography, Cardiac Magnetic Resonance Imaging, and Computed Tomography

The role of cardiac PET in diagnosis and prognosis of patients with ischemia with no obstructive coronary arteries (INOCA)